Beamion PANTUMOR-1: A Phase II, multicenter, multi-cohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumors
Condition(s)
Bile Duct Cancer (Cholangiocarcinoma), Breast, Breast Cancer, Cervical Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Solid Tumor, Urothelial Cancer, Uterine Cancer
Molecular Target(s)
HER2
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
Zongertinib (BI 1810631)
Phase(s)
II
Mechanism of Action
- BI 1810631 is an EGFR wild type sparing, selective HER2 inhibitor with potent inhibitory activity on all oncogenic HER2 mutations including the HER2 YVMA insertion allele.
Purpose
In this study, the sponsor and investigators want to learn:
- How much of the study drug/agent can be given with an acceptable level of side effects
- The effects of the study drug/agent (good and bad)
- How much of the study drug/agent is absorbed into the blood and how fast it is removed
- How the study drug/agent is acting on your body
Study Design
This is a Phase II, open-label, multi-centre, multi-cohort trial to evaluate the preliminary efficacy and safety of zongertinib for the treatment of selected HER2-mutated or overexpressed/amplified tumors.
The trial will include 10 cohorts of different tumor types. There will be 8 tumor-specific cohorts (Cohorts 1 to 5 and Cohorts 7 to 9) and 2 tumor agnostic cohorts (Cohorts 10 and 6).
Zongertinib will be administered daily in 21-day cycles.
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000